TY  - JOUR
AU  - Forero-Castro, Maribel
AU  - Robledo, Cristina
AU  - Lumbreras, Eva
AU  - Benito, Rocio
AU  - Hernández-Sánchez, Jesús M
AU  - Hernández-Sánchez, María
AU  - García, Juan L
AU  - Corchete-Sánchez, Luis A
AU  - Tormo, Mar
AU  - Barba, Pere
AU  - Menárguez, Javier
AU  - Ribera, Jordi
AU  - Grande, Carlos
AU  - Escoda, Lourdes
AU  - Olivier, Carmen
AU  - Carrillo, Estrella
AU  - García de Coca, Alfonso
AU  - Ribera, Josep-María
AU  - Hernández-Rivas, Jesús M
PY  - 2015
DO  - 10.1111/bjh.13849
UR  - http://hdl.handle.net/10668/9621
T2  - British journal of haematology
AB  - The introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients...
LA  - en
KW  - Burkitt lymphoma
KW  - array-based comparative genomic hybridization (aCGH)
KW  - next-generation sequencing
KW  - outcome
KW  - rituximab
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Burkitt Lymphoma
KW  - Chromosome Aberrations
KW  - Comparative Genomic Hybridization
KW  - Female
KW  - Genome
KW  - High-Throughput Nucleotide Sequencing
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Rituximab
KW  - Treatment Outcome
KW  - Young Adult
TI  - The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
TY  - research article
VL  - 172
ER  -